Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Acta Psychiatrica Scandinavica
|
January 19, 2020
Aksel Brockhusen Bertelsen *25 July 1936 †9 October 2019
P Munk-Jørgensen, B Christiansen, M C Arendt, et al.
European Journal of Clinical Pharmacology
|
January 5, 2002
Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers
M S Benedetti, M Plisnier, J Kaise, et al.
Clinical Pharmacology and Therapeutics
|
February 1, 1978
Drug trial in rheumatoid arthritis: a new design
E C Arendt-Racine, M H Atkinson, W E Decoteau, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 23, 2018
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials
A Blauvelt, K Reich, M Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 30, 2021
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
R B Warren, M Lebwohl, H Sofen, et al.
Trials
|
July 16, 2008
Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis
Carsten Hjorthøj, Allan Fohlmann, Anne-Mette Larsen, et al.
Progress in Cardiovascular Diseases
|
May 1, 2025
Impact of cardiac rehabilitation participation on functional capacity in patients with hypertrophic obstructive cardiomyopathy following septal myectomy surgery
Gizem Cifci, Katherine R Malterer, Elizabeth C Arendt, et al.
The British Journal of Dermatology
|
June 13, 2020
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies
A Blauvelt, C Paul, P van de Kerkhof, et al.
Annals of the Rheumatic Diseases
|
August 14, 2016
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers
P Emery, C O Bingham, G R Burmester, et al.
Annals of the Rheumatic Diseases
|
May 12, 2016
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
P Emery, C O Bingham, G R Burmester, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Acta Psychiatrica Scandinavica
|
January 19, 2020
Aksel Brockhusen Bertelsen *25 July 1936 †9 October 2019
P Munk-Jørgensen, B Christiansen, M C Arendt, et al.
European Journal of Clinical Pharmacology
|
January 5, 2002
Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers
M S Benedetti, M Plisnier, J Kaise, et al.
Clinical Pharmacology and Therapeutics
|
February 1, 1978
Drug trial in rheumatoid arthritis: a new design
E C Arendt-Racine, M H Atkinson, W E Decoteau, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 23, 2018
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials
A Blauvelt, K Reich, M Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 30, 2021
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
R B Warren, M Lebwohl, H Sofen, et al.
Trials
|
July 16, 2008
Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis
Carsten Hjorthøj, Allan Fohlmann, Anne-Mette Larsen, et al.
Progress in Cardiovascular Diseases
|
May 1, 2025
Impact of cardiac rehabilitation participation on functional capacity in patients with hypertrophic obstructive cardiomyopathy following septal myectomy surgery
Gizem Cifci, Katherine R Malterer, Elizabeth C Arendt, et al.
The British Journal of Dermatology
|
June 13, 2020
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies
A Blauvelt, C Paul, P van de Kerkhof, et al.
Annals of the Rheumatic Diseases
|
August 14, 2016
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers
P Emery, C O Bingham, G R Burmester, et al.
Annals of the Rheumatic Diseases
|
May 12, 2016
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
P Emery, C O Bingham, G R Burmester, et al.
Page
of 2